← Back to Methodology
RQS Scoring Log

SLU-PP-332

Peptide-Adjacent· Animal / In Vitro· Scored May 2026· View compound profile →
36 /100
Weak Evidence
7 dimensions · 100 points total · Methodology by PeptideClear
Dimension Breakdown
DimensionScoring NotesScore
Study Design
Mouse studies only — exercise mimetic effects via ERR agonism. No human trials. Very new compound (primary paper 2023). Animal/in vitro.
 5 / 25
Sample Size
No human participants.
 0 / 20
Replication
Single research group (Thomas Burris, St. Louis University/UF) primarily. Very early stage — limited independent replication opportunity given recency.
 10 / 20
Journal Impact Factor
Published in Nature Communications (IF ~16) and Journal of Pharmacology and Experimental Therapeutics (IF ~4.5). Strong journals for preclinical work.
 8 / 15
Funding Independence
NIH and academic (St. Louis University, University of Florida) funded. No commercial interests at this stage.
 10 / 10
Population Diversity
Animal only. Not applicable.
 0 / 5
Researcher h-Index
Thomas Burris (UF) has h-Index ~50+ in nuclear receptor pharmacology. Credible researcher. Capped at 5.
 3 / 5
Animal Only Note
This score reflects evidence in humans. Animal and in vitro evidence may be substantially stronger than the score suggests — this compound has not yet been studied in human trials.
Scored by the PeptideClear editorial team using publicly available literature. Sources: PubMed (study design, sample size, replication) · ScimagoJR (journal impact factor) · Google Scholar (researcher h-Index) · Primary papers (funding disclosure). Scores are reviewed as new research is published.